Granted Patent
B2
US 12,239,763 · App. 18/141,270 · Granted Mar 4, 2025
Peptides and antibodies for the removal of biofilms
A61L27/54A61K8/64A61K39/12A61K39/395A61K39/40A61L29/16A61P31/04A61Q11/00A61Q17/005C07K16/12C07K16/1217C07K16/1232C07K16/1242C07K16/1271C07K16/1275C07K16/18C12N15/62A61K2039/507A61L2300/404C07K2317/34C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.
Claims (86)
1. A composition comprising one or more of a preservative, an adjuvant, or a stabilizer; and an isolated polynucleotide encoding one or more polypeptides selected from:
(i)
SEQ ID NO. 13
a polypeptide consisting of (RPGRNPKTGDVVPVSARRVV);
(ii)
SEQ ID NO. 16
a polypeptide consisting of (RGFGSFSLHHRQPRLGRNPK);
or
(iii)
SEQ ID NO. 17
a polypeptide consisting of (FSLHHRQPRLGRNPKTGDSV).
2. A composition comprising a vector comprising an isolated, non-naturally occurring polynucleotide encoding one or more polypeptides selected from:
(i)
SEQ ID NO. 13
a polypeptide consisting of (RPGRNPKTGDVVPVSARRVV);
(ii)
SEQ ID NO. 16
a polypeptide consisting of (RGFGSFSLHHRQPRLGRNPK);
or
(iii)
SEQ ID NO. 17
a polypeptide consisting of (FSLHHRQPRLGRNPKTGDSV),
and one or more of a preservative, an adjuvant, or a stabilizer.
3. A composition comprising an isolated host cell comprising an isolated, non-naturally occurring polynucleotide encoding one or more polypeptides selected from:
(i)
SEQ ID NO. 13
a polypeptide consisting of (RPGRNPKTGDVVPVSARRVV);
(ii)
SEQ ID NO. 16
a polypeptide consisting of (RGFGSFSLHHRQPRLGRNPK);
or
(iii)
SEQ ID NO. 17
a polypeptide consisting of (FSLHHRQPRLGRNPKTGDSV),
and one or more of a preservative, an adjuvant, or a stabilizer.
4. The composition of claim 1 , wherein the isolated polynucleotide further comprises a detectable label or a purification label.
5. The composition of claim 2 , wherein the isolated polynucleotide further comprises a detectable label or a purification label.
6. The composition of claim 3 , wherein the isolated polynucleotide further comprises a detectable label or a purification label.
7. The composition of claim 2 , and a carrier or adjuvant.
8. The composition of claim 3 , and a carrier or adjuvant.
9. The composition of claim 1 , further comprising one or more of
(a) a deoxyribonuclease (DNase),
(b) amoxicillin,
(c) amoxicillin-clavulanate,
(d) cefdinir,
(e) azithromycin,
(f) sulfamethoxazole-trimethoprim,
(g) an antibody directed against outer membrane protein (“OMP”) P5,
(h) an antibody directed against rsPilA,
(i) an antibody directed against OMP 26,
(i) an antibody directed against OMP P2, or
(k) an antibody directed against Type IV Pilin protein.
10. The composition of claim 1 , further comprising a carrier selected from a liquid carrier or a solid phase carrier, a pharmaceutically acceptable polymer, a liposome, a micelle, an implant, a stent, a paste, or a gel.
11. The composition of claim 2 , further comprising a carrier selected from a liquid carrier or a solid phase carrier, a pharmaceutically acceptable polymer, a liposome, a micelle, an implant, a stent, a paste, or a gel.
12. A method of delivering an isolated polynucleotide to a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .
13. A method of delivering an isolated polynucleotide to a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 2 .
14. The method of claim 13 , further comprising administering an effective amount of an antimicrobial.
15. The method of claim 14 , further comprising administering an effective amount of one or more of the following:
(a) an antibody directed against OMP P5, rsPilA, OMP 26, OMP P2, or Type IV Pilin protein;
(b) one or more of amoxicillin, amoxicillin-clavulanate, cefdinir, azithromycin, or sulfamethoxazole-trimethoprim;
(c) a deoxyribonuclease (DNase) enzyme; or
(d) a polypeptide selected from
(i)
SEQ ID NO. 12
(FLEEIRLSLESGQDVKLSGF);
(ii)
SEQ ID NO. 13
(RPGRNPKTGDVVPVSARRVV);
(iii)
SEQ ID NO. 14
(RTGRNPQTGAEIQIAASKVP);
(iv)
SEQ ID NO. 15
(TLSAKEIENMVKDILEFISQ);
(v)
SEQ ID NO. 16
(RGFGSFSLHHRQPRLGRNPK);
(vi)
SEQ ID NO. 17
(FSLHHRQPRLGRNPKTGDSV);
(vii)
SEQ ID NO. 33
(KKQAKAALEATLDAITASLKEG).
16. The method of claim 13 , wherein the subject is suffering from sinusitis, bronchitis, otitis media, exacerbations of chronic obstructive pulmonary disease (COPD), dental caries, pneumonia, cystic fibrosis, skin and soft tissue infections, gonorrhea, urinary tract infection, or chronic granulomatous disease.
17. The method of claim 13 , wherein the subject has a biofilm generated by one or more microorganisms selected from Haemophilus influenza, Streptococcus mutans, Staphylococcus aureus, Moraxella catarrhalis, Streptococcus pneumonia, Pseudomonas aeruginosa, Neisseria gonorrhoeae, E. coli, Staphylococcus epidermidis , and Burkholderia cenocepacia.
18. The method of claim 17 , wherein Staphylococcus aureus is methicillin-resistant S. aureus (MRSA).
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 31, 2024
From: BAKALETZ, LAUREN O.; GOODMAN, STEVEN D.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 069097/0357 →
Continuity (6)
Continuation
15744713
Provisional Application
62199957
· Jul 31, 2015
Provisional Application
62387562
· Dec 23, 2015
Provisional Application
62361400
· Jul 12, 2016
References Cited (400)
US 5549908A
· Smith et al.
· 1996
[cited by applicant]
US 6486314B1
· Van Geel-Schutten et al.
· 2002
[cited by applicant]
US 6551795B1
· Rubenfield et al.
· 2003
[cited by applicant]
US 6663863B2
· Horvath et al.
· 2003
[cited by applicant]
US 6696550B2
· Larosa et al.
· 2004
[cited by applicant]
US 6846651B2
· Fleischmann et al.
· 2005
[cited by applicant]
US 7241867B2
· Bakaletz et al.
· 2007
[cited by applicant]
US 7413868B2
· Kauvar et al.
· 2008
[cited by applicant]
US 7435595B2
· Boehm et al.
· 2008
[cited by applicant]
US 7638282B2
· Bakaletz et al.
· 2009
[cited by applicant]
US 7811591B2
· Bakaletz et al.
· 2010
[cited by applicant]
US 7816086B2
· Bakaletz et al.
· 2010
[cited by applicant]
US 7939344B2
· Kauvar et al.
· 2011
[cited by applicant]
US 7981676B2
· Boehm et al.
· 2011
[cited by applicant]
US 7998490B2
· Bakaletz et al.
· 2011
[cited by applicant]
US 8236494B2
· Bakaletz et al.
· 2012
[cited by applicant]
US 8283114B2
· Bakaletz et al.
· 2012
[cited by applicant]
US 8329187B2
· Lazzari et al.
· 2012
[cited by applicant]
US 8628917B2
· Bakaletz et al.
· 2014
[cited by applicant]
US 8652773B2
· Bakaletz et al.
· 2014
[cited by applicant]
US 8758764B2
· Masignani et al.
· 2014
[cited by applicant]
US 8933029B2
· Mcnicol et al.
· 2015
[cited by applicant]
US 8999291B2
· Goodman et al.
· 2015
[cited by applicant]
US 9017656B2
· Hancock et al.
· 2015
[cited by applicant]
US 9034642B2
· Bakaletz et al.
· 2015
[cited by applicant]
US 9155792B2
· Cottarel et al.
· 2015
[cited by applicant]
US 9278069B2
· Berkland et al.
· 2016
[cited by applicant]
US 9504739B2
· Berkes et al.
· 2016
[cited by applicant]
US 9554590B2
· Quintens et al.
· 2017
[cited by applicant]
US 9603878B2
· Berry et al.
· 2017
[cited by applicant]
US 9610307B2
· Berry et al.
· 2017
[cited by applicant]
US 9687449B2
· Harel
· 2017
[cited by applicant]
US 9713631B2
· Berkes et al.
· 2017
[cited by applicant]
US 9717765B2
· Berkes et al.
· 2017
[cited by applicant]
US 9745366B2
· Goodman et al.
· 2017
[cited by applicant]
US 20020132753A1
· Rosen et al.
· 2002
[cited by applicant]
US 20030060410A1
· Tracey et al.
· 2003
[cited by applicant]
US 20030099602A1
· Levin et al.
· 2003
[cited by applicant]
US 20030229065A1
· Levy et al.
· 2003
[cited by applicant]
US 20050059633A1
· Van Geel-Schuten
· 2005
[cited by applicant]
US 20050112235A1
· Shefer et al.
· 2005
[cited by applicant]
US 20050131222A1
· Fleischmann et al.
· 2005
[cited by applicant]
US 20050266069A1
· Simmons et al.
· 2005
[cited by applicant]
US 20060030539A1
· Nick et al.
· 2006
[cited by applicant]
US 20060121047A1
· Tracey
· 2006
[cited by applicant]
US 20060228384A1
· Eldridge
· 2006
[cited by applicant]
US 20060240045A1
· Berthet et al.
· 2006
[cited by applicant]
US 20070154529A1
· Bullerdiek
· 2007
[cited by applicant]
US 20070286822A1
· Sanders et al.
· 2007
[cited by applicant]
US 20090029929A1
· Nakajima et al.
· 2009
[cited by applicant]
US 20090297555A1
· Kemble et al.
· 2009
[cited by applicant]
US 20100291177A1
· Hermans et al.
· 2010
[cited by applicant]
US 20100303723A1
· Farokhzad et al.
· 2010
[cited by applicant]
US 20110008493A1
· Zorea
· 2011
[cited by applicant]
US 20110027328A1
· Baig et al.
· 2011
[cited by applicant]
US 20120128701A1
· Goodman et al.
· 2012
[cited by applicant]
US 20120148615A1
· Masignani et al.
· 2012
[cited by applicant]
US 20120189558A1
· Prendergast
· 2012
[cited by applicant]
US 20120247993A1
· Palazzi et al.
· 2012
[cited by applicant]
US 20130183323A1
· Wang
· 2013
[cited by applicant]
US 20140120107A1
· Bakaletz et al.
· 2014
[cited by applicant]
US 20150086561A1
· Kauvar et al.
· 2015
[cited by applicant]
US 20150166641A1
· Goodman et al.
· 2015
[cited by applicant]
US 20150197558A1
· Kauvar et al.
· 2015
[cited by applicant]
US 20150218231A1
· Bakaletz et al.
· 2015
[cited by applicant]
US 20150290140A1
· Singh et al.
· 2015
[cited by applicant]
US 20150299298A1
· Kauvar et al.
· 2015
[cited by applicant]
US 20160089363A1
· Borody
· 2016
[cited by applicant]
US 20160175440A1
· Goodman et al.
· 2016
[cited by applicant]
US 20160194384A1
· Goodman et al.
· 2016
[cited by applicant]
US 20160235792A1
· Berry et al.
· 2016
[cited by applicant]
US 20160271188A1
· Berry et al.
· 2016
[cited by applicant]
US 20160289278A1
· Bakaletz et al.
· 2016
[cited by applicant]
US 20160340650A1
· Wagner et al.
· 2016
[cited by applicant]
US 20170182205A1
· Zupancic et al.
· 2017
[cited by applicant]
US 20170196915A1
· Czarnecki-Maulden et al.
· 2017
[cited by applicant]
US 20170215417A1
· Bhushan et al.
· 2017
[cited by applicant]
US 20170296600A1
· Rangavajla
· 2017
[cited by applicant]
US 20180207067A1
· Goodman et al.
· 2018
[cited by applicant]
DE 202013103204U1
· 2013
[cited by applicant]
WO WO9850018A1
· 1998
[cited by applicant]
WO WO0047104A2
· 2000
[cited by applicant]
WO WO02077183A2
· 2002
[cited by applicant]
WO WO02085295
· 2002
[cited by applicant]
WO WO03026691A1
· 2003
[cited by applicant]
WO WO03026691A2
· 2003
[cited by applicant]
WO WO03083045A2
· 2003
[cited by applicant]
WO WO2004014418A2
· 2004
[cited by applicant]
WO WO2004044001A2
· 2004
[cited by applicant]
WO WO2004072094A2
· 2004
[cited by applicant]
WO WO2004078949A2
· 2004
[cited by applicant]
WO WO2005025604A2
· 2005
[cited by applicant]
WO WO2005111066A2
· 2005
[cited by applicant]
WO WO2006017816A2
· 2006
[cited by applicant]
WO WO2006083301A2
· 2006
[cited by applicant]
WO WO2006114805A2
· 2006
[cited by applicant]
WO WO2006138527
· 2006
[cited by applicant]
WO WO2007001422A2
· 2007
[cited by applicant]
WO WO2009006699A1
· 2009
[cited by applicant]
WO WO2010138522A2
· 2010
[cited by applicant]
WO WO2010139956
· 2010
[cited by applicant]
WO WO2011029059
· 2011
[cited by applicant]
WO WO2011123396A1
· 2011
[cited by applicant]
WO WO2012034090A1
· 2012
[cited by applicant]
WO WO2013088045A1
· 2013
[cited by applicant]
WO WO2013177596A2
· 2013
[cited by applicant]
WO WO2014016417A1
· 2014
[cited by applicant]
WO WO2014067976A1
· 2014
[cited by applicant]
WO WO2014121304A1
· 2014
[cited by applicant]
WO WO2014201305A1
· 2014
[cited by applicant]
WO WO2015038339A1
· 2015
[cited by applicant]
WO WO2015048484A2
· 2015
[cited by applicant]
WO WO2015089502A2
· 2015
[cited by applicant]
WO WO2016154491A1
· 2016
[cited by applicant]
WO WO2016184795A1
· 2016
[cited by applicant]
WO WO2017023863A1
· 2017
[cited by applicant]
WO WO2017066719A2
· 2017
[cited by applicant]
WO WO2017192594A1
· 2017
[cited by applicant]
WO WO2018042385A2
· 2018
[cited by applicant]
WO WO2018129078A1
· 2018
[cited by applicant]
WO WO2018129092A1
· 2018
[cited by applicant]
WO WO2018170178A1
· 2018
[cited by applicant]
WO WO2018187615A1
· 2018
[cited by applicant]
WO WO2019112978A2
· 2019
[cited by applicant]
WO WO2020038963A1
· 2020
[cited by applicant]
WO WO2020092554A1
· 2020
[cited by applicant]
WO WO2021007260A2
· 2021
[cited by applicant]
U.S. Appl. No. 18/141,270, filed Apr. 28, 2023, Lauren O. Bakaletz.
[cited by applicant]
U.S. Office Action issued in U.S. Appl. No. 18/168,824, dated Oct. 23, 2023, 22 pages.
[cited by applicant]
U.S. Appl. No. 16/820,463, filed Mar. 16, 2020, Research Institute at Nationwide Children's Hospital and Ohio State Innovation Foundation.
[cited by applicant]
Adams et al., “D-158. Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable
[cited by applicant]
Adams et al., “Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable
[cited by applicant]
Albandar, “Epidemiology and risk factors of periodontal diseases”, Dental clinics of North America, vol. 49, No. 3, Jun. 28, 2005, pp. 517-532.
[cited by applicant]
Allaker et al., “Non-conventional therapeutics for oral infections,” Virulence, vol. 6, No. 3, Apr. 2015, pp. 196-207.
[cited by applicant]
Andersson et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes”, The Journal of Experimental Medicine, vol. 192, No. 4, Aug. 21, 2000, pp. 565-570.
[cited by applicant]
Andersson, U. et al. (2011) “HMGB1 is a Therapeutic Target for Sterile Inflammation and Infection,” Annu. Rev. Immunol. 29:139-162.
[cited by applicant]
Australian Examination Report dated Sep. 27, 2022, from application No. 2020203092, 5 pages.
[cited by applicant]
Bakaletz et al., “New strategies to target bacterial biofilms”, 28th Annual North American Cystic Fibrosis Conference (NACFC), Atlanta, GA, Oct. 9-11, 2014 (presentation), 2 pages.
[cited by applicant]
Bakaletz et al., “Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable
[cited by applicant]
Bakaletz et al., “Protection against Development of Otitis Media Induced by Nontypeable
[cited by applicant]
Bakaletz, “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid associated proteins”, 6th ASM Conference on Biofilms, Miami, FL, Sep. 29-Oct. 4, 2012 (presentation), 5 pages.
[cited by applicant]
Bakaletz, L.O., Targeting the biofilm for development of novel preventative and therapeutic vaccine candidates to prevent otitis media, 6th ASM Conference on Biofilms, Miami, FL, Sep. 29-Oct. 4, 2012 (presentation), 5 p…
[cited by applicant]
Barve et al., “Cloning and characterization of the mating type (MAT) locus from
[cited by applicant]
Bass, J.I.F. et al. (2010) “Extracellular DNA: A Major Proinflammatory Component of
[cited by applicant]
Beech, I.B. et al. (2005) “Microbe-surface interactions in biofouling and biocorrosion processes,” International Microbiology 8:157-168.
[cited by applicant]
Beer et al., “Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo,” Gene Therapy, vol. 5, Jan. 5, 1998, pp. 740-746.
[cited by applicant]
Ben et al., “Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and Lactobacilli,” World Journal of Gastroenterology, vol. 14, No. 42, Nov. 14, 2008, pp. 6564-6568.
[cited by applicant]
Bendig, Mary M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Methods: A Companion to Methods in Enzymology, 1995, vol. 8, pp. 83-93.
[cited by applicant]
Bjarnsholt, T. (2013) “The role of bacterial biofilms in chronic infections,” APMIS 121 (Suppl. 136):1-51.
[cited by applicant]
Boles, B.R. et al. (2011) “
[cited by applicant]
Brady, R.A. et al. (2006) “Identification of
[cited by applicant]
Brandstetter et al., “Antibodies Directed Against Integration Host Factor Mediate Biofilm Clearance From Nasopore,” The Laryngoscope, vol. 12, No. 11, Nov. 2013, pp. 2626-2632.
[cited by applicant]
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663): 1532-5. doi: 10.1126/science.1092385. PubMed PMID: 1…
[cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258, Supp…
[cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258.
[cited by applicant]
Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, Devaraj A, Goodman SD, Bakaletz LO, Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacter…
[cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VHCDR2”, J. Immunol. May 1996, 155(9):3285-3291.
[cited by applicant]
Busby, et al., “Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq”, bioRxiv preprint posted Oct. 17, 2016, 51 pages.
[cited by applicant]
Catlin, “Extracellular Deoxyribonucleic Acid of Bacteria and a Deoxyribonuclease Inhibitor,” Science, vol. 124, Sep. 7, 1956, pp. 441-442.
[cited by applicant]
Ceri, H. et al. (1999) “The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms,” Journal of Clinical Microbiology 37(6):1771-1776.
[cited by applicant]
Chavarri et al., “Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions,” International Journal of Food Microbiology, vol. 142, Jun. 22…
[cited by applicant]
Chen et al., “Novel Strategies for the Prevention and Treatment of Biofilm Related Infections,” Int. J. Mol. Sci., vol. 14, Sep. 6, 2013, pp. 18488-18501.
[cited by applicant]
Chen et al., “The effect of immobilization of probiotic
[cited by applicant]
Chen, C. et al. (2004) “Substrate specificity of
[cited by applicant]
Chen, et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations”, The EMBO Journal, 1995, vol. 14, No. 12, pp. 2784-2794.
[cited by applicant]
Cho et al., “The modulation of the biological activities of mitochondrial histone Abf2p by yeast PKA and its possible role in the regulation of mitochondrial DNA content during glucose repression,” Biochimica et Biophys…
[cited by applicant]
Coenye, T. et al. (2010) “In vitro and in vivo model systems to study microbial biofilm formation,” Journal of Microbiological Methods 83:89-105.
[cited by applicant]
Cohavy, O. et al. (1999) “Identification of a Novel Mycobacterial Histone H1 Homologue (HupB) as an Antigenic Target of pANCA Monoclonal Antibody and Serum Immunoglobulin A from Patients with Cohn's Disease,” Infection …
[cited by applicant]
Collarini, E.J. et al. (2009) “Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients,” J Immunol 183:6338-6345.
[cited by applicant]
Cook et al., “Microencapsulation of a synbiotic into PLGA/alginate multiparticulate gels,” International Jounral of Pharmaceutics, vol. 466, Mar. 20, 2014, pp. 400-408.
[cited by applicant]
Cook et al., “Microencapsulation of probiotics for gastrointestinal delivery,” Journal of Controlled Release, vol. 162, Jun. 11, 2012, pp. 56-67.
[cited by applicant]
Cornaz Gudet et al., “Simple method of in vitro diffusion of nicotine across procine palatine mucosa”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 43, No. 3, Jan. 16, 1997, pp. 259-264.
[cited by applicant]
Crittenden et al., “Synbiotic Microcapsules That Enhance Microbial Viability during Nonrefrigerated Storage and Gastrointestinal Transit”, Applied and Environmental Microbiology, vol. 72, No. 3, Mar. 2006, 2280-2282.
[cited by applicant]
Dalai, B. et al. (2009) “Histone-like protein H-NS regulates biofilm formation and virulence of
[cited by applicant]
Darouiche, R.O. et al. (2004) “Treatment of Infections Associated with Surgical Implants,” N Engl J Med 350:1422-1429.
[cited by applicant]
Darveau RP. The oral microbial consortium's interaction with the periodontal innate defense system. DNA and cell biology.2009;28(8):389-95. Epub May 14, 2009. doi:10.1089/dna.2009.0864. PubMed PMID: 19435427; PMCID: 288…
[cited by applicant]
Darveau, “Periodontitis: a polymicrobial disruption of host homeostasis”, Nature reviews Microbiology, vol. 8, No. 7, Jul. 2010, pp. 481-490.
[cited by applicant]
De La Fuente-Nunez et al., “Broad-Spectrum Anti-biofilm Peptide That Targets a Cellular Stress Response,” PLoS Pathog., vol. 10, No. 5, May 2014, pp. 1-12.
[cited by applicant]
Devaraj A, justice SS, Bakaletz LO, Goodman SD. DNABII proteins play a central role in UPEC biofilm structure. Molecular microbiology. 2015. doi: 10.1111/mmi.12994. PubMed PMID: 25757804.
[cited by applicant]
Devaraj et al., “DNABII proteins play a central role in UPEC biofilm structure”, Molecular Microbiology, 2015, vol. 96, vol. 6, Jun. 2015, pp. 1119-1135.
[cited by applicant]
Dominguez-Herrera, J. et al. (2011) “Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant
[cited by applicant]
Donlan, R.M. et al. (2002) “Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms,” Clinical Microbiology Reviews 15(2):167-193.
[cited by applicant]
Dresser et al., “Investigation of the genes involved in antigenic switching at the vlsE locus in
[cited by applicant]
Durocher et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells,” Nucleic Acids Research, vol. 30, No. 2, e9, Nov. 11, 2001, 9 pages.
[cited by applicant]
Dzink et al., “The predominant cultivable microbiota of active and inactive lesions of destructive periodontal diseases”, Journal of clinical periodontology, vol. 15, No. 5, Sep. 8, 1987, pp. 316-323.
[cited by applicant]
Eboigbodin, K.E. et al. (2008) “Characterization of the Extracellular Plymeric Substances Produced by
[cited by applicant]
Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ, Cdc Periodontal Disease Surveillance workgroup: James Beck GDRP. Prevalence of periodontitis in adults in the United States: 2009 and 2010. Journal of dental research.…
[cited by applicant]
Estelles et al., “A High-Affinity Native Human Antibody Disrupts Biofilm from
[cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections”, Pharamceuticals, vol. 3, No. 5, May 11, 2010, pp. 1374-1393.
[cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections,” Pharmaceuticals, vol. 3, May 11, 2010, pp. 1374-1393.
[cited by applicant]
Falciola et al., “Mutational analysis of the DNA binding domain A of chromosomal protein HMG1,” Nucleic Acids Research, vol. 22, No. 3, Jan. 10, 1994, pp. 285-292.
[cited by applicant]
Fan, Z. et al. (2002) “HMG2 Interacts with the Nucleosome Assembly Protein SET and is a Target of the Cytotoxic T-Lymphocyte Protease Granzyme A,” Molecular and Cellular Biology 22(8):2810-2820.
[cited by applicant]
Fedorov, O. et al. (2012) “Kinase Inhibitor Selectivity Profiling Using Differential Scanning Fluorimetry,” Kinase Inhibitors: Methods and Protocols, Methods in Molecular Biology 795:109-118.
[cited by applicant]
Final Office Action in U.S. Appl. No. 14/885,800 dated May 4, 2017, 17 pages.
[cited by applicant]
Franssen, et al., “Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres”, Journal of Controlled Release, 60, 1999, pp. 211-221.
[cited by applicant]
Garcia-Contreras et al., “Protein Translation and Cell Death: The Role of Rare tRNAs in Biofilm Formation and in Activating Dormant Phage Killer Genes,” PLoS ONE, vol. 3, No. 6, Jun. 11, 2008, e2394, 17 pages.
[cited by applicant]
George et al., “Cystic fibrosis infections: treatment strategies and prospects,” FEMS Microbiology Letters, vol. 300, No. 2, Jun. 15, 2009, pp. 153-164.
[cited by applicant]
Gerstel et al., “Complex Regulation of csgD Promoter Activity by Global Regulatory Proteins,” Molecular Microbiology, vol. 49, No. 3, Aug. 2003, pp. 639-654.
[cited by applicant]
Goldenberg et al., “Genetic and biochemical analysis of IHF/HU hybrid proteins”, BioChimie, vol. 76, No. 10-11, Jan. 1, 1994, pp. 941-950.
[cited by applicant]
Good et al., “Synthetic RNA silencing in bacteria—antimicrobial discovery and resistance breaking,” Frontiers in Microbiology, vol. 2, No. 185, Sep. 12, 2011, pp. 1-11.
[cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Advances in Mucosal Immunology, Jun. 29, 2011, pp. 1-13.
[cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins,” Mucosal Immunology, vol. 4, No. 6, Nov. 2011, pp. 625-637.
[cited by applicant]
Goodman et al., “In Vitro Selection of Integration Host Factor Binding Sites,” Journal of Bacteriology, vol. 181, No. 10, May 1999, pp. 3246-3255.
[cited by applicant]
Goodman et al., “Replacement of Integration Host Factor Protein-induced DNA Bending by Flexible Regions of DNA,” The Journal of Biological Chemistry, vol. 274, No. 52, Aug. 6, 1999, pp. 37004-37011.
[cited by applicant]
Goodman S D et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Mucosal Immuno, Nature Publishing Group, vol. 4, No. 6, Nov. 1, 2011, pp. 625-6…
[cited by applicant]
Goodman SD, Obergfell KP, Jurcisek JA, Novotny LA, Downey JS, Ayala EA, Tjokro N, Li B, Justice SS, Bakaletz LO. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associate…
[cited by applicant]
Goodman, “A new immunotherapeutic approach that disperses biofilms, Banff Conference on Infectious Diseases”, Banff, Alberta, Canada, May 18, 2012 (presentation), 9 pages.
[cited by applicant]
Goodman, “Making and breaking biofilms”, Ohio Branch American Society for Microbiology Annual Meeting, Columbus, OH, Apr. 11-12, 2014 (presentation), 12 pages.
[cited by applicant]
Goodman, “Nucleoprotein complexes in the extracellular matrix are critical for the structural integrity of bacterial biofilms”, 112th General Meeting, American Society for Microbiology, San Francisco, CA, Jun. 18, 2012 …
[cited by applicant]
Goodman, “The DNABII family of proteins: Diagnostic markers and therapeutic targets of bacterial biofilms”, International Congress on Bacteriology and Infectious Disease, Baltimore, MD, Nov. 21, 2013, 7 pages.
[cited by applicant]
Goshima et al., “Chimeric HU-IHF proteins that alter DNA-binding ability,” Gene, vol. 118, No. 1, Sep. 1, 1992, pp. 97-102.
[cited by applicant]
Govan et al., “Microbial pathogenesis in cystic fibrosis: mucoid
[cited by applicant]
Granston et al., “Characterization of a Set of Integration Host Factor Mutants Deficient for DNA Binding,” J. Mol. Biol., vol. 234, Jun. 21, 1993, pp. 45-59.
[cited by applicant]
Greenspan et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, vol. 17, Oct. 1999, pp. 936-937.
[cited by applicant]
Grossi et al., “Assessment of risk for periodontal disease. I. Risk indicators for attachment loss”, Journal of periodontology, vol. 65, No. 3, Sep. 15, 1993, pp. 260-267.
[cited by applicant]
Gustave et al., “Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 12, No. 4, Nov. 17, 2012, pp. 384-389.
[cited by applicant]
Gustave et al., Biofilms recovered from the sputum of CF patients contain the bacterial protein integration host factor (IHF), 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, Nov. 3-5, 2011 (poster),…
[cited by applicant]
Gustave JE, Jurcisek JA, McCoy KS, Goodman SD, Bakaletz LO. Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis. Journal of cystic fibrosis : official journal of the European …
[cited by applicant]
Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nature reviews Microbiology.2012; 10(10):717-25. Epub Sep. 4, 2012. doi: 10.1038/nrmicro2873. PubMed PMID: 22941505; PMCID: 3498498.
[cited by applicant]
Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nature reviews Immunology.2011;11(3):187-200. Epub Feb. 26, 2011. doi:10.1038/nri2918. PubMed PMID: 21350579; PMCID: 3077082.
[cited by applicant]
Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskan MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD, Darveau RP, Curtis MA. Low-abundance biofilm species orchestrates inflammatory periodontal disease throu…
[cited by applicant]
Hall-Stoodley et al., “Bacterial Biofilms: From the Natural Environment to Infectious Diseases,” Nature Reviews, Microbiology, vol. 2, Feb. 2004, pp. 95-108.
[cited by applicant]
Hall-Stoodley et al., “Direct Detection of Bacterial Biofilms on the Middle-Ear Mucosa of Children With Chronic Otitis Media,” JAMA, vol. 296, No. 2, Jun. 1, 2007, pp. 202-211.
[cited by applicant]
Hall-Stoodley et al., “Evolving concepts in biofilm infections”, Cellular Microbiology, vol. 11, No. 7, 2009, pp. 1034-1043.
[cited by applicant]
Hall-Stoodley et al., “Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in
[cited by applicant]
Haluzi et al., “Genes Coding for Integration Host Factor Are Conserve in Gram-Negative Bacteria,” Journal of Bacteriology, vol. 173, No. 19, Oct. 1991, pp. 6297-6299.
[cited by applicant]
Harley et al., “The Molecular Action and Regulation of the Testis-Determining Factors, SRY (Sex—Determining Region on the Y Chromosome) and SOX9 [SRY-Related High-Mobility Group (HMG) Box 9],” Endocrine Reviews, vol. 24…
[cited by applicant]
Harriman, W.D. et al. (2008) “Antibody discovery via multiplexed single cell characterization,” Journal of Immunological Methods 341:135-145.
[cited by applicant]
Harrison, J.J. et al. (2010) “Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening,” Nature Protocols 5(7):1236-1254.
[cited by applicant]
Haruta et al., “A possible role of histone-like DNA-binding protein of
[cited by applicant]
Haruta et al., “Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation,” Laboratory Investigation, vol. 90, Apr. 2010, pp. 577-588.
[cited by applicant]
Haurum. “Recombinant polyclonal antibodies: the next generation of antibody therapeutics?” Drug Discovery Today. Jul. 2006; 11(13-14):655-60.
[cited by applicant]
Hoyle et al., “Bacterial Resistance to Antibiotics: The Role of Biofilms,” Prog. Drug Res., vol. 37, 1991, pp. 91-105.
[cited by applicant]
Idicula, W.K. et al. (2016) “Identification of Biofilms in Post-tympanostomy Tube Otorrhea,” The Laryngoscope 126(8):1946-1951.
[cited by applicant]
Janeway, “Manipulating the immune response to fight infection,” Immunobiology: The Immune System in Health and Disease, 5th ed.; retrieved online from https://www.ncbi.nlm.nih.gov/books/NBK27131/, 2001, 13 pages.
[cited by applicant]
Janeway, et al., “Immunobiology—The Immune System in Health and Disease,” Third Edition, 1997, Garland Publish Inc., 14 pages.
[cited by applicant]
Jiao et al., “Identification of Biofilm Matrix-Associated Proteins from an Acid Mine Drainage Microbial Community,” Appl & Environ Microbiol., vol. 77, Aug. 2011, pp. 5230-5237.
[cited by applicant]
Jodar et al., “Development of vaccines against meningococcal disease,” Lancet, vol. 359, Apr. 27, 2002, pp. 1499-1508.
[cited by applicant]
John, A-K. et al. (2011) “Reversible Daptomycin Tolerance of Adherent
[cited by applicant]
Johnson et al., “Chapter 8: Bending and Compaction of DNA by Proteins,” Protein-Nucleic Acid Interactions: Structural Biology, 2008, pp. 176-220.
[cited by applicant]
Joo, H-S. et al. (2012) “Molecular Basis of in Vivo Formation by Bacterial Pathogens,” Chemistry & Biology 19:1503-1513.
[cited by applicant]
Jurcisek et al., “Role of Sialic Acid and Complex Carbohydrate Biosynthesis in Biofilm Formation by Nontypeable
[cited by applicant]
Jurcisek et al., “Biofilms Formed by Nontypeable
[cited by applicant]
Jurcisek JA, Bakaletz LO. Biofilms formed by nontypeable
[cited by applicant]
Justice et al., “Aberrant Community Architecture and Attenuated Persistence of Uropathogenic
[cited by applicant]
Kadajji et al., “Water Soluble Polymers for Pharmaceutical Applications”, Polymers, vol. 3, No. 4, Nov. 11, 2011, pp. 1972-2009.
[cited by applicant]
Kadajji et al., “Water Soluble Polymers for Pharmaceutical Applications,” Polymers, vol. 3, Nov. 11, 2011, pp. 1972-2009.
[cited by applicant]
Kamashev D, Rouviere-Yaniv J. The histone-like protein HU binds specifically to DNA recombination and repair intermediates. The EMBO journal.2000;19(23):6527-35.
[cited by applicant]
Kamashev et al., “The histone-like protein HU binds specifically to DNA recombination and repair intermediates,” The EMBO Journal, vol. 19, No. 23, Oct. 13, 2000, pp. 6527-6535.
[cited by applicant]
Kennedy et al., “Passive Transfer of Antiserum Specific for Immunogens Derived from a Nontypeable
[cited by applicant]
Khrapunov, S. et al. (2006) “Binding then bending: A mechanism for wrapping DNA,” PNAS 103(51):19217-19218.
[cited by applicant]
Kim et al., “Beta-Arm flexibility of HU from
[cited by applicant]
Kim et al., “Proteins Released by
[cited by applicant]
Kirketerp-Moller et al., “Distribution, Organization, and Ecology of Bacteria in Chronic Wounds,” Journal of Clinical Microbiology, vol. 46, No. 8, Aug. 2008, pp. 2717-2722.
[cited by applicant]
Kornblit et al., “The genetic variation of the human HMG1 gene,” Tissue Antigens, vol. 70, Apr. 12, 2007, pp. 151-156.
[cited by applicant]
Kristian, S.A. et al. (2003) “Alanylation of Teichoic Acids Protects
[cited by applicant]
Kumari et al., “Biodegradable polymeric nanoparticles based drug delivery systems,” Colloids and Surfaces B: Biointerfaces, vol. 75, Sep. 8, 2009, pp. 1-18.
[cited by applicant]
Kussie, et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, Journal of Immunology, 1994, vol. 152, pp. 146-152.
[cited by applicant]
Kyd et al., “Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens to Induce Clearance of Nontypeable
[cited by applicant]
Labbé et al., “Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-ß and Wnt pathways,” Proc. Natl. Acad. Sci. USA, vol. 9…
[cited by applicant]
Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of
[cited by applicant]
Lappann M, Claus H, van Alen T, Harmsen M, Elias J, Molin S, Vogel U. A dual role of extracellular DNA during biofilm formation of
[cited by applicant]
Laura A. Novotny et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo”, EBioMedicine, vol. 10, Aug. 1, 2016, pp. 33-44.
[cited by applicant]
Lebeaux et al., “From in vitro to in vivo Models of Bacterial Biofilm-Related Infections,” Pathogens, vol. 2, May 13, 2013, pp. 288-356.
[cited by applicant]
Li et al., “Retroviral cDNA Integration: Stimulation by HMG I Family Proteins,” Journal of Virology, vol. 74, No. 23, Dec. 2000, pp. 10965-10974.
[cited by applicant]
Lipman, et al., “Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources”, ILAR Journal, 2005, pp. 258-268.
[cited by applicant]
Liu et al., “The essentiality and involvement of
[cited by applicant]
Liu, D. et al. (2008) “Histone-like DNA binding protein of
[cited by applicant]
Lunsford et al., “DNA-Binding Activities in
[cited by applicant]
Lutz, H.U. et al. (1990) “Covalent binding of detergent-solubilized membrane glycoproteins to ‘Chemobond’ plates for ELISA,” Journal of Immunological Methods 129:211-220.
[cited by applicant]
M. Elizabeth Brockson et al., “Evaluation of the kinetics and mechanism of action anti-integration host factor-mediated disruption of bacterial biofilms: Anti-IHF-mediated biofilm collapse”, Molecular Microbiology., Aug…
[cited by applicant]
Maeda et al., “Oral
[cited by applicant]
Mahdi et al., “Holliday Junction Resolvases Encoded by Homologous rusA Genes in
[cited by applicant]
Malhotra et al., “Defining the functional epitopes of Integration Host Factor (IHF) to develop a novel biofilm-focused immunotherapeutic against nontypeable
[cited by applicant]
Malhotra et al., “Fine mapping the functional epitopes within integration host factor, a novel therapeutic target for nontypeable
[cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, 20th Annual Midwest Microbial Pathogenesis Meeting. The Ohio State University, Columbus, OH,…
[cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Abst. Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stoc…
[cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stockholm,…
[cited by applicant]
Mann, E.E. et al. (2009) “Modulation of eDNA Release and Degradation Affects
[cited by applicant]
Martinez-Antonio A. et al. (2008), “Functional organization of
[cited by applicant]
Meluleni et al., (1995) “Mucoid
[cited by applicant]
Mouw et al., “Shaping the
[cited by applicant]
Mukherjee et al., “Quantitative protein expression and cell surface characteristics of
[cited by applicant]
Murphy et al., “Microbial Interactions in the Respiratory Tract,” The Pediatric Infectious Disease Journal, vol. 28, No. 10, Oct. 2009, pp. S121-S126.
[cited by applicant]
Murphy, T.F. et al. (2002) “Biofilm formation by nontypeable
[cited by applicant]
Nakagawa et al., “Clinical, microbiological and immunological studies on recurrent periodontal disease”, Journal of clinical periodontology, Jul. 31, 1989, vol. 17, No. 7 Pt 1, pp. 426-434.
[cited by applicant]
Nakamura et al., “HMG Box A in HMG3 Protein Functions as a Mediator of DNA Structural Alteration Together with Box B,” J. Biochem., vol. 129, No. 4, Feb. 5, 2001, pp. 643-651.
[cited by applicant]
Nakashima, N. et al., “Bacterial Cellular Engineering by Genome Editing and Gene Silencing,” Int. J. Mol. Sci., vol. 15, Feb. 18, 2014, pp. 2773-2793.
[cited by applicant]
Nash et al., “Overproduction of
[cited by applicant]
Novotny et al. “Antibodies against the majority subunit of type IV Pili disperse nontypeable
[cited by applicant]
Novotny et al., “Antibodies against the majority subunit of Type 1V pili disperse nontypeable
[cited by applicant]
Novotny et al., “Epitope mapping immunodominant regions of the PilA protein of nontypeable
[cited by applicant]
Novotny et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” EBioMedicine, vol. 10, pp. 33-44 (Aug. 1, 2016).
[cited by applicant]
Novotny et al., “Structural Stability of
[cited by applicant]
Novotny et al., “Detection and characterization of pediatric serum antibody to the OMP P5-homologous adhesin of nontypeable
[cited by applicant]
Novotny et al., “Epitope mapping immunodominant regions of the PilA protein of nontypeable
[cited by applicant]
Novotny et al., “Epitope mapping of the Outer Membrane Protein P5-Homologous Fimbrin Adhesin of Nontypeable
[cited by applicant]
Novotny et al., “Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with
[cited by applicant]
Novotny et al., “The Fourth Surface-Exposed Region of the Outer Membrane Protein P5-Homologous Adhesin of the Nontypable
[cited by applicant]
Novotny LA, Amer AO, Brockson ME, Goodman SD, Bakaletz LO. Structural stability of
[cited by applicant]
Novotny, “Development of a novel biofilm-focused immunotherapeutic against NTHI-induced otitis media”, 18th International Symposium on Recent Advances in Otitis Media, National Harbor, MD, Jun. 7-11, 2015 (presentation)…
[cited by applicant]
Novotny, et al., “Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable
[cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” 2016, EBioMedicine 10:33-44.
[cited by applicant]
Novotny, et al., “Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable
[cited by applicant]
Nowakowska, J. et al. (2014) “Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm,” Antibiotics 3:378-397, Aug. 2014.
[cited by applicant]
Oberto et al., “Histones, HMG, HU, IHF: Même combat,” Biochimie, vol. 76, 1994, pp. 901-908.
[cited by applicant]
Ofran, Y. et al., “Automated Identification of Complementarity Determining Regions (CDRs) Reveals Peculiar Characteristics of CDRs and B Cell Epitopes”, J Immunol, 181 (9), pp. 6230-6235, Nov. 1, 2008 (Jan. 11, 2008).
[cited by applicant]
Ordway et al., “Evaluation of Standard Chemotherapy in the Guinea Pig Model of Tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 54, May 2010, pp. 1820-1833.
[cited by applicant]
Ornelas-Megiatto et al., “Aerosolized Antimicrobial Agents Based on Degradable Dextran Nanoparticles Loaded with Silver Carbene Complexes”, Molecular Pharmaceutics, vol. 9, No. 11, Oct. 1, 2012, pp. 3012-3022.
[cited by applicant]
Otto, “
[cited by applicant]
Park Y, Simionato MR, Sekiya K, Murakami Y, James D, Chen W, Hackett M, Yoshimura F, Demuth DR, Lamont RJ. Short fimbriae of
[cited by applicant]
Pedulla et al., “A novel host factor for integration of mycobacteriophage L5,” Proc. Natl. Acad. Sci. USA, vol. 93, Dec. 1996, pp. 15411-15416.
[cited by applicant]
Petersen et al., “Biofilm Mode of Growth of
[cited by applicant]
Petersen PE, Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. Journal of periodontology.2005;76(12):2187-93. Epub Dec. 8, 2005. doi: 10.1902/jop.2005.76.12.2187. PubMed PMID: 16332229.
[cited by applicant]
Pethe et al., “Mycobacterium smegmatis laminin-binding glycoprotein shares epitopes with Mycobacterium tuberculosis heparin-binding haemagglutinin,” Molecular Microbiology, vol. 39, No. 1, 2001, pp. 89-99.
[cited by applicant]
Petreska Ivanovska et al., “Comparative evaluation of viability of encapsulated
[cited by applicant]
Pliszczak et al., “Improvement of an encapsulation process for the preparation of pro- and prebiotics-loaded bioadhesive microparticles by using experimental design,” European Journal of Pharmaceutical Sciences, vol. 44…
[cited by applicant]
Priyadarshini R, Cugini C, Amdt A, Chen T, Tjokro No., Goodman SD, Davey ME, The nucleoid-associated protein HUß affects global gene expression in
[cited by applicant]
Prymula et al., “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both
[cited by applicant]
Reffuveille et al., “A Broad-Spectrum Antibiofilm Peptide Enhances Antibiotic Action against Bacterial Biofilms”, Antimicrobial Agents and Chemotherapy, vol. 58, No. 9, Sep. 2014, pp. 5363-5371.
[cited by applicant]
Rezaee et al., “Prebiotics Decrease the Antibacterial Effect of Nano Silver nd Nano TiO2 Particles Against Probiotic Bacteria of Food”, Current Nutrition and Food Science, vol. 10, No. 2, Jul. 15, 2013, pp. 88-93.
[cited by applicant]
Rice et al., “Crystal Structure of an IHF-DNA Complex: A Protein-Induced DNA U-Turn,” Cell, vol. 87, No. 7, pp. 1295-1306 (Dec. 27, 1996).
[cited by applicant]
Rice et al., “Crystal Structure of an IHF-DNA Complex: A Protein-Induced DNA U-Turn,” Cell, vol. 87, No. 7, Dec. 27, 1996, pp. 1295-1306.
[cited by applicant]
Rocco et al. “Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics” Mol Oral Microbiol . Apr. 2017;32(2):118-…
[cited by applicant]
Rocco et al., “Natural antigenic differences in the fucntionally equivalent extracellular DNABI I proteins of bacterial biofilms provide a means for targeted biofilm therapeutics,” Molecular Oral Microbiology, vol. 32, …
[cited by applicant]
Rouviere-Yaniv J, Gros F. Characterization of a novel, low-molecular-weight DNA-binding protein from
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, vol. 79, No. 6, Mar. 1982, pp. 1979-1983.
[cited by applicant]
Salmeron, “Fermented cereal beverages: from probiotic, prebiotic and synbiotic towards Nanoscience designed healthy drinks”, Letters in Applied Microbiology, vol. 65, Mar. 31, 2017, pp. 114-124.
[cited by applicant]
Sapi et al., “Characterization of Biofilm Formation by
[cited by applicant]